Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 62
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Dev Dyn ; 253(3): 312-332, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-37776236

RESUMEN

INTRODUCTION: Primary cilia play pivotal roles in the patterning and morphogenesis of a wide variety of organs during mammalian development. Here we examined murine foregut septation in the cobblestone mutant, a hypomorphic allele of the gene encoding the intraflagellar transport protein IFT88, a protein essential for normal cilia function. RESULTS: We reveal a crucial role for primary cilia in foregut division, since their dramatic decrease in cilia in both the foregut endoderm and mesenchyme of mutant embryos resulted in a proximal tracheoesophageal septation defects and in the formation of distal tracheo(broncho)esophageal fistulae similar to the most common congenital tracheoesophageal malformations in humans. Interestingly, the dorsoventral patterning determining the dorsal digestive and the ventral respiratory endoderm remained intact, whereas Hedgehog signaling was aberrantly activated. CONCLUSIONS: Our results demonstrate the cobblestone mutant to represent one of the very few mouse models that display both correct endodermal dorsoventral specification but defective compartmentalization of the proximal foregut. It stands exemplary for a tracheoesophageal ciliopathy, offering the possibility to elucidate the molecular mechanisms how primary cilia orchestrate the septation process. The plethora of malformations observed in the cobblestone embryo allow for a deeper insight into a putative link between primary cilia and human VATER/VACTERL syndromes.


Asunto(s)
Ciliopatías , Proteínas Hedgehog , Humanos , Animales , Ratones , Proteínas Hedgehog/genética , Cilios , Alelos , Modelos Animales de Enfermedad , Mamíferos
2.
Toxicol Appl Pharmacol ; 490: 117034, 2024 Jul 14.
Artículo en Inglés | MEDLINE | ID: mdl-39009139

RESUMEN

Late-stage clinical trial failures increase the overall cost and risk of bringing new drugs to market. Determining the pharmacokinetic (PK) drivers of toxicity and efficacy in preclinical studies and early clinical trials supports quantitative optimization of drug schedule and dose through computational modeling. Additionally, this approach permits prioritization of lead candidates with better PK properties early in development. Mylotarg is an antibody-drug conjugate (ADC) that attained U.S. Food and Drug Administration (FDA) approval under a fractionated dosing schedule after 17 years of clinical trials, including a 10-year period on the market resulting in hundreds of fatal adverse events. Although ADCs are often considered lower risk for toxicity due to their targeted nature, off-target activity and liberated payload can still constrain dosing and drive clinical failure. Under its original schedule, Mylotarg was dosed infrequently at high levels, which is typical for ADCs because of their long half-lives. However, our PK modeling suggests that these regimens increase maximum plasma concentration (Cmax)-related toxicities while producing suboptimal exposures to the target receptor. Our analysis demonstrates that the benefits of dose fractionation for Mylotarg tolerability should have been obvious early in the drug's clinical development and could have curtailed the proliferation of ineffective Phase III studies. We also identify schedules likely to be even more efficacious without compromising on tolerability. Alternatively, a longer-circulating Mylotarg formulation could obviate the need for dose fractionation, allowing superior patient convenience. Early-stage PK optimization through quantitative modeling methods can accelerate clinical development and prevent late-stage failures.

3.
J Pathol ; 244(5): 667-676, 2018 04.
Artículo en Inglés | MEDLINE | ID: mdl-29377130

RESUMEN

Humans coexist with a vast bacterial, fungal and viral microbiome with which we have coevolved for millions of years. Several long recognized epidemiological associations between particular bacteria and cancer are now understood at the molecular level. At the same time, the arrival of next-generation sequencing technology has permitted a thorough exploration of microbiomes such as that of the human gut, enabling observation of taxonomic and metabolomic relationships between the microbiome and cancer. These studies have revealed causal mechanisms for both microbes within tumours and microbes in other host niches separated from tumours, mediated through direct and immunological mechanisms. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.


Asunto(s)
Bacterias/patogenicidad , Transformación Celular Neoplásica , Microbioma Gastrointestinal , Tracto Gastrointestinal/microbiología , Neoplasias/microbiología , Animales , Antibacterianos/uso terapéutico , Bacterias/clasificación , Bacterias/efectos de los fármacos , Bacterias/metabolismo , Transformación Celular Neoplásica/efectos de los fármacos , Transformación Celular Neoplásica/genética , Transformación Celular Neoplásica/metabolismo , Transformación Celular Neoplásica/patología , Microbioma Gastrointestinal/efectos de los fármacos , Tracto Gastrointestinal/efectos de los fármacos , Interacciones Huésped-Patógeno , Humanos , Neoplasias/genética , Neoplasias/metabolismo , Neoplasias/terapia , Probióticos/uso terapéutico
4.
Antimicrob Agents Chemother ; 60(6): 3856-61, 2016 06.
Artículo en Inglés | MEDLINE | ID: mdl-27067331

RESUMEN

Ceftazidime is one of the few cephalosporins with activity against Pseudomonas aeruginosa Using whole-genome comparative analysis, we set out to determine the prevalent mechanism(s) of resistance to ceftazidime (CAZ) using a set of 181 clinical isolates. These isolates represented various multilocus sequence types that consisted of both ceftazidime-susceptible and -resistant populations. A presumptive resistance mechanism against ceftazidime was identified in 88% of the nonsusceptible isolates using this approach.


Asunto(s)
Proteínas Bacterianas/genética , Regulación Bacteriana de la Expresión Génica , Genoma Bacteriano , N-Acetil Muramoil-L-Alanina Amidasa/genética , Pseudomonas aeruginosa/genética , Resistencia betalactámica/genética , beta-Lactamasas/genética , Secuencia de Aminoácidos , Antibacterianos/farmacología , Ceftazidima/farmacología , Citrobacter freundii/genética , Genotipo , Humanos , Pruebas de Sensibilidad Microbiana , Tipificación de Secuencias Multilocus , Infecciones por Pseudomonas/microbiología , Pseudomonas aeruginosa/efectos de los fármacos , Pseudomonas aeruginosa/crecimiento & desarrollo , Pseudomonas aeruginosa/aislamiento & purificación , Alineación de Secuencia
5.
Antimicrob Agents Chemother ; 59(1): 427-36, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25367914

RESUMEN

Many clinical isolates of Pseudomonas aeruginosa cause infections that are difficult to eradicate due to their resistance to a wide variety of antibiotics. Key genetic determinants of resistance were identified through genome sequences of 390 clinical isolates of P. aeruginosa, obtained from diverse geographic locations collected between 2003 and 2012 and were related to microbiological susceptibility data for meropenem, levofloxacin, and amikacin. ß-Lactamases and integron cassette arrangements were enriched in the established multidrug-resistant lineages of sequence types ST111 (predominantly O12) and ST235 (O11). This study demonstrates the utility of next-generation sequencing (NGS) in defining relevant resistance elements and highlights the diversity of resistance determinants within P. aeruginosa. This information is valuable in furthering the design of diagnostics and therapeutics for the treatment of P. aeruginosa infections.


Asunto(s)
Amicacina/farmacología , Antibacterianos/farmacología , Levofloxacino/farmacología , Pseudomonas aeruginosa/efectos de los fármacos , Tienamicinas/farmacología , Amicacina/uso terapéutico , Antibacterianos/uso terapéutico , Técnicas de Tipificación Bacteriana , Secuencia de Bases , ADN Bacteriano/genética , Farmacorresistencia Bacteriana Múltiple/genética , Genoma Bacteriano/genética , Humanos , Levofloxacino/uso terapéutico , Meropenem , Pruebas de Sensibilidad Microbiana , Tipificación de Secuencias Multilocus , Infecciones por Pseudomonas/tratamiento farmacológico , Infecciones por Pseudomonas/microbiología , Pseudomonas aeruginosa/genética , Pseudomonas aeruginosa/aislamiento & purificación , Análisis de Secuencia de ADN , Tienamicinas/uso terapéutico , beta-Lactamasas/genética
6.
Antimicrob Agents Chemother ; 59(3): 1478-86, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25534723

RESUMEN

The unmet medical need for novel intervention strategies to treat Neisseria gonorrhoeae infections is significant and increasing, as rapidly emerging resistance in this pathogen is threatening to eliminate the currently available treatment options. AZD0914 is a novel bacterial gyrase inhibitor that possesses potent in vitro activities against isolates with high-level resistance to ciprofloxacin and extended-spectrum cephalosporins, and it is currently in clinical development for the treatment of N. gonorrhoeae infections. The propensity to develop resistance against AZD0914 was examined in N. gonorrhoeae and found to be extremely low, a finding supported by similar studies with Staphylococcus aureus. The genetic characterization of both first-step and second-step mutants that exhibited decreased susceptibilities to AZD0914 identified substitutions in the conserved GyrB TOPRIM domain, confirming DNA gyrase as the primary target of AZD0914 and providing differentiation from fluoroquinolones. The analysis of available bacterial gyrase and topoisomerase IV structures, including those bound to fluoroquinolone and nonfluoroquinolone inhibitors, has allowed the rationalization of the lack of cross-resistance that AZD0914 shares with fluoroquinolones. Microbiological susceptibility data also indicate that the topoisomerase inhibition mechanisms are subtly different between N. gonorrhoeae and other bacterial species. Taken together, these data support the progression of AZD0914 as a novel treatment option for the oral treatment of N. gonorrhoeae infections.


Asunto(s)
Barbitúricos/farmacología , Neisseria gonorrhoeae/efectos de los fármacos , Compuestos de Espiro/farmacología , Inhibidores de Topoisomerasa II/farmacología , Girasa de ADN/química , Girasa de ADN/genética , Farmacorresistencia Bacteriana , Isoxazoles , Pruebas de Sensibilidad Microbiana , Morfolinas , Mutación , Neisseria gonorrhoeae/genética , Oxazolidinonas
7.
Nat Med ; 13(7): 836-42, 2007 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-17603494

RESUMEN

Psoriasis is a common T cell-mediated autoimmune inflammatory disease. We show that blocking the interaction of alpha1beta1 integrin (VLA-1) with collagen prevented accumulation of epidermal T cells and immunopathology of psoriasis. Alpha1beta1 integrin, a major collagen-binding surface receptor, was exclusively expressed by epidermal but not dermal T cells. Alpha1beta1-positive T cells showed characteristic surface markers of effector memory cells and contained high levels of interferon-gamma but not interleukin-4. Blockade of alpha1beta1 inhibited migration of T cells into the epidermis in a clinically relevant xenotransplantation model. This was paralleled by a complete inhibition of psoriasis development, comparable to that caused by tumor necrosis factor-alpha blockers. These results define a crucial role for alpha1beta1 in controlling the accumulation of epidermal type 1 polarized effector memory T cells in a common human immunopathology and provide the basis for new strategies in psoriasis treatment focusing on T cell-extracellular matrix interactions.


Asunto(s)
Células Epidérmicas , Integrina alfa1beta1/metabolismo , Psoriasis/metabolismo , Linfocitos T/metabolismo , Animales , Anticuerpos Monoclonales , Eliminación de Gen , Regulación de la Expresión Génica , Humanos , Integrina alfa1beta1/antagonistas & inhibidores , Ratones , Trasplante Heterólogo
8.
Cancer Cell ; 9(1): 23-32, 2006 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-16413469

RESUMEN

Cyclin D1 is overexpressed in the majority of human breast cancers. We previously found that mice lacking cyclin D1 are resistant to mammary carcinomas triggered by the ErbB-2 oncogene. In this study, we investigated which function of cyclin D1 is required for ErbB-2-driven mammary oncogenesis. We report that the ability of cyclin D1 to activate cyclin-dependent kinase CDK4 underlies the critical role for cyclin D1 in breast cancer formation. We also found that the continued presence of CDK4-associated kinase activity is required to maintain breast tumorigenesis. We analyzed primary human breast cancers and found high cyclin D1 levels in a subset (approximately 25%) of ErbB-2-overexpressing tumors. We propose that this subset of breast cancer patients might benefit from inhibiting CDK4 kinase.


Asunto(s)
Neoplasias de la Mama/enzimología , Proliferación Celular , Ciclina D1/metabolismo , Quinasa 4 Dependiente de la Ciclina/metabolismo , Neoplasias Mamarias Experimentales/enzimología , Animales , Neoplasias de la Mama/genética , Neoplasias de la Mama/patología , Ciclina D1/genética , Quinasa 4 Dependiente de la Ciclina/genética , Activación Enzimática , Femenino , Genes erbB-2 , Humanos , Neoplasias Mamarias Experimentales/patología , Ratones , Ratones Noqueados , Unión Proteica
9.
Adv Exp Med Biol ; 819: 21-39, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25023165

RESUMEN

Integrin α1ß1 is widely expressed in mesenchyme and the immune system, as well as a minority of epithelial tissues. Signaling through α1 contributes to the regulation of extracellular matrix composition, in addition to supplying in some tissues a proliferative and survival signal that appears to be unique among the collagen binding integrins. α1 provides a tissue retention function for cells of the immune system including monocytes and T cells, where it also contributes to their long-term survival, providing for peripheral T cell memory, and contributing to diseases of autoimmunity. The viability of α1 null mice, as well as the generation of therapeutic monoclonal antibodies against this molecule, have enabled studies of the role of α1 in a wide range of pathophysiological circumstances. The immune functions of α1 make it a rational therapeutic target.


Asunto(s)
Integrina alfa1beta1/fisiología , Animales , Colágeno/metabolismo , Humanos , Sistema Inmunológico/fisiología , Integrina alfa1beta1/análisis , Integrina alfa1beta1/genética , Laminina/metabolismo , Ratones , Neovascularización Fisiológica , Transducción de Señal
11.
Front Cell Infect Microbiol ; 12: 1000445, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36710975

RESUMEN

Rapid evaluation of antimicrobial susceptibility is important in the treatment of nosocomial infections by Gram-negative bacteria, which increasingly carry carbapenemases and metallo-ß-lactamases. We developed loop-mediated isothermal amplification (LAMP)-based assays for four ß-lactamase genes (bla KPC, bla NDM-1, bla IMP-1 group, and bla VIM). The assays were evaluated using eight reference bacterial strains (Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter bereziniae) harboring six ß-lactamase genes. A total of 55 Gram-negative bacterial strains, including 47 clinical P. aeruginosa isolates, fully characterized by next-generation sequencing (NGS), were used to evaluate the LAMP assays. The results were compared to those of conventional PCR. The LAMP assays were able to detect as few as 10 to 100 copies of a gene, compared to 10 to 104 copies for conventional PCR. The LAMP assay detected four ß-lactamase genes with a sensitivity similar to that using purified DNA as the template in DNA-spiked urine, sputum, and blood specimens. By contrast, the sensitivity of PCR was 1- to 100-fold lower with DNA-spiked clinical specimens. Therefore, the LAMP assays were proved to be an appropriate tool for the detection of four ß-lactamases.


Asunto(s)
Proteínas Bacterianas , beta-Lactamasas , beta-Lactamasas/genética , Proteínas Bacterianas/genética , Técnicas de Amplificación de Ácido Nucleico/métodos , Técnicas de Diagnóstico Molecular , Bacterias Gramnegativas/genética , Escherichia coli/genética , Pruebas de Sensibilidad Microbiana , Antibacterianos/farmacología
12.
J Neurosci ; 30(12): 4221-31, 2010 Mar 24.
Artículo en Inglés | MEDLINE | ID: mdl-20335457

RESUMEN

Apoptosis of neurons in the maturing neocortex has been recorded in a wide variety of mammals, but very little is known about its effects on cortical differentiation. Recent research has implicated the RhoA GTPase subfamily in the control of apoptosis in the developing nervous system and in other tissue types. Rho GTPases are important components of the signaling pathways linking extracellular signals to the cytoskeleton. To investigate the role of the RhoA GTPase subfamily in neocortical apoptosis and differentiation, we have engineered a mouse line in which a dominant-negative RhoA mutant (N19-RhoA) is expressed from the Mapt locus, such that all neurons of the developing nervous system are expressing the N19-RhoA inhibitor. Postnatal expression of N19-RhoA led to no major changes in neocortical anatomy. Six layers of the neocortex developed and barrels (whisker-related neural modules) formed in layer IV. However, the density and absolute number of neurons in the somatosensory cortex increased by 12-26% compared with wild-type littermates. This was not explained by a change in the migration of neurons during the formation of cortical layers but rather by a large decrease in the amount of neuronal apoptosis at postnatal day 5, the developmental maximum of cortical apoptosis. In addition, overexpression of RhoA in cortical neurons was seen to cause high levels of apoptosis. These results demonstrate that RhoA-subfamily members play a major role in developmental apoptosis in postnatal neocortex of the mouse but that decreased apoptosis does not alter cortical cytoarchitecture and patterning.


Asunto(s)
Apoptosis/fisiología , GTP Fosfohidrolasas/metabolismo , Regulación del Desarrollo de la Expresión Génica/fisiología , Neocórtex/enzimología , Neuronas/fisiología , Proteína de Unión al GTP rhoA/metabolismo , Vías Aferentes/embriología , Vías Aferentes/enzimología , Vías Aferentes/crecimiento & desarrollo , Factores de Edad , Animales , Animales Recién Nacidos , Recuento de Células/métodos , Diferenciación Celular/fisiología , Movimiento Celular/genética , Embrión de Mamíferos , Regulación del Desarrollo de la Expresión Génica/genética , Genes Dominantes , Proteínas Fluorescentes Verdes/genética , Humanos , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Mutación/genética , Neocórtex/citología , Neocórtex/crecimiento & desarrollo , Proteína de Unión al GTP rhoA/genética , Proteínas tau/metabolismo
13.
Breast Cancer Res Treat ; 119(2): 379-90, 2010 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-19844788

RESUMEN

Mutations in the alpha catalytic subunit of phosphoinositol-3-kinase (PIK3CA) occur in approximately 30% of ER positive breast cancers. We therefore sought to determine the impact of PIK3CA mutation on response to neoadjuvant endocrine therapy. Exons 9 (helical domain) and 20 (kinase domain-KD) mutations in PIK3CA were determined samples from four neoadjuvant endocrine therapy trials.Interactions with clinical, pathological, and biomarker response parameters were examined. A weak negative interaction between PIK3CA mutation status and clinical response to neoadjuvant endocrine treatment was detected(N = 235 P < or = 0.05), but not with treatment-induced changes in Ki67-based proliferation index (N = 418). Despite these findings, PIK3CA KD mutation was a favorable prognostic factor for relapse-free survival (RFS log-rank P = 0.02) in the P024 trial (N = 153). The favorable prognostic effect was maintained in a multivariable analysis(N = 125) that included the preoperative endocrine prognostic index, an approach to predicting RFS based on post neoadjuvant endocrine therapy pathological stage, ER, and Ki67 levels (HR for no PIK3CA KD mutation, 14, CI 1.9-105 P = 0.01). PIK3CA mutation status did not strongly interact with neoadjuvant endocrine therapy responsiveness in estrogen receptor-positive breast cancer. Nonetheless, as with other recent studies, a favorable interaction between PIK3CA KD mutation and prognosis was detected. The mechanism for the favorable prognostic impact of PIK3CA mutation status therefore remains unexplained.


Asunto(s)
Antineoplásicos Hormonales/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Mutación , Fosfatidilinositol 3-Quinasas/genética , Receptores de Estrógenos/análisis , Neoplasias de la Mama/química , Neoplasias de la Mama/enzimología , Neoplasias de la Mama/genética , Neoplasias de la Mama/patología , Proliferación Celular/efectos de los fármacos , Quimioterapia Adyuvante , Fosfatidilinositol 3-Quinasa Clase I , Ensayos Clínicos Fase II como Asunto , Supervivencia sin Enfermedad , Exones , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Estimación de Kaplan-Meier , Antígeno Ki-67/análisis , Terapia Neoadyuvante , Estadificación de Neoplasias , Fosforilación , Modelos de Riesgos Proporcionales , Proteínas Proto-Oncogénicas c-akt/análisis , Ensayos Clínicos Controlados Aleatorios como Asunto , Receptor ErbB-2/análisis , Receptores de Progesterona/análisis , Medición de Riesgo , Factores de Tiempo , Resultado del Tratamiento
14.
Int Psychogeriatr ; 22(6): 966-72, 2010 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-20561382

RESUMEN

BACKGROUND: Deposition of amyloid beta in senile plaques and in cerebral blood vessels is one hallmark of the pathogenesis of Alzheimer's disease (AD). The ability of several matrix metalloproteinases (MMPs) to degrade amyloid precursor protein leading to aggregation of amyloid beta, as well as the increased expression of MMPs in post mortem brain tissue of Alzheimer's patients, indicate that MMPs play an important role in the pathogenesis of AD. METHODS: We investigated levels of MMP-2,-3,-9 and -10 in plasma and cerebrospinal fluid (CSF) of AD patients (n = 14) by gelatin and casein zymography. Comparisons between AD patients and controls relative to levels of MMP-2, MMP-3, MMP-9, and MMP-10 were made with Wilcoxon rank statistics. Pearson correlations were computed as measures of association. RESULTS: MMP-3 in AD was significantly elevated in plasma (p = 0.006) and there was a trend towards increase in CSF (p = 0.05). MMP-2 in CSF of AD patients was significantly decreased (p = 0.02) while levels in plasma remained unchanged. MMP-9 and MMP-10 could not be detected in CSF; MMP-10 was unchanged in plasma, but MMP-9 was significantly decreased (p = 0.02). CONCLUSIONS: These findings constitute further evidence for the important role of MMPs in the pathogenesis of AD.


Asunto(s)
Enfermedad de Alzheimer/fisiopatología , Metaloproteinasas de la Matriz/metabolismo , Anciano , Péptidos beta-Amiloides/metabolismo , Angiopatía Amiloide Cerebral/fisiopatología , Femenino , Humanos , Imagen por Resonancia Magnética , Masculino , Metaloproteinasa 1 de la Matriz/metabolismo , Metaloproteinasa 10 de la Matriz/metabolismo , Metaloproteinasa 2 de la Matriz/metabolismo , Metaloproteinasa 3 de la Matriz/metabolismo , Metaloproteinasa 9 de la Matriz/metabolismo , Escala del Estado Mental , Persona de Mediana Edad , Valores de Referencia
15.
J Neurosci ; 28(48): 12887-900, 2008 Nov 26.
Artículo en Inglés | MEDLINE | ID: mdl-19036983

RESUMEN

Primary cilia are important sites of signal transduction involved in a wide range of developmental and postnatal functions. Proteolytic processing of the transcription factor Gli3, for example, occurs in primary cilia, and defects in intraflagellar transport (IFT), which is crucial for the maintenance of primary cilia, can lead to severe developmental defects and diseases. Here we report an essential role of primary cilia in forebrain development. Uncovered by N-ethyl-N-nitrosourea-mutagenesis, cobblestone is a hypomorphic allele of the IFT gene Ift88, in which Ift88 mRNA and protein levels are reduced by 70-80%. cobblestone mutants are distinguished by subpial heterotopias in the forebrain. Mutants show both severe defects in the formation of dorsomedial telencephalic structures, such as the choroid plexus, cortical hem and hippocampus, and also a relaxation of both dorsal-ventral and rostral-caudal compartmental boundaries. These defects phenocopy many of the abnormalities seen in the Gli3 mutant forebrain, and we show that Gli3 proteolytic processing is reduced, leading to an accumulation of the full-length activator isoform. In addition, we observe an upregulation of canonical Wnt signaling in the neocortex and in the caudal forebrain. Interestingly, the ultrastructure and morphology of ventricular cilia in the cobblestone mutants remains intact. Together, these results indicate a critical role for ciliary function in the developing forebrain.


Asunto(s)
Corteza Cerebral/anomalías , Corteza Cerebral/metabolismo , Cilios/metabolismo , Regulación del Desarrollo de la Expresión Génica/genética , Factores de Transcripción de Tipo Kruppel/metabolismo , Proteínas del Tejido Nervioso/metabolismo , Proteínas Supresoras de Tumor/genética , Animales , Corteza Cerebral/ultraestructura , Cilios/ultraestructura , Epéndimo/metabolismo , Epéndimo/ultraestructura , Femenino , Factores de Transcripción de Tipo Kruppel/genética , Ventrículos Laterales/anomalías , Ventrículos Laterales/metabolismo , Ventrículos Laterales/ultraestructura , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Mutantes , Ratones Transgénicos , Proteínas del Tejido Nervioso/genética , Neuronas/metabolismo , Neuronas/ultraestructura , Péptido Hidrolasas/metabolismo , Prosencéfalo/anomalías , Prosencéfalo/metabolismo , Prosencéfalo/ultraestructura , Proteínas Supresoras de Tumor/metabolismo , Proteínas Wnt/metabolismo , Proteína Gli3 con Dedos de Zinc
16.
J Cell Mol Med ; 13(9B): 3449-62, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19397781

RESUMEN

Connective tissue cell activation is of importance during reactive conditions such as solid tumour growth, wound healing and pannus formation in rheumatoid arthritis. Here, we have compared connective tissue cells of mesenchymal origin in human tissues from these conditions and their normal counterparts using a panel of cell-type-specific markers. In particular, we investigated variations of integrin expression among connective tissue cell phenotypes. Connective tissue cell populations were defined based on their association with the microvasculature and their expression of activation markers. The phenotype of these cells varied according to the type of pathological connective tissue examined. Our morphological data from human tissues suggested that the alpha(1)beta(1) integrin, a collagen/laminin receptor, is involved in the differentiation of precursor cells into myofibroblasts. To mechanistically investigate this hypothesis, we employed experimental models for carcinoma growth and wound healing utilizing alpha(1) integrin-deficient mice. The data confirmed that the alpha(1)beta(1) integrin is of importance not only for the differentiation of mesenchymal cells into myofibroblasts but also for the neovascularization and connective tissue organization and emphasize the importance of myofibroblasts in the pathophysiology of tissue repair, inflammation and tumour growth.


Asunto(s)
Adenocarcinoma/metabolismo , Artritis Reumatoide/metabolismo , Colágeno/química , Integrina alfa1beta1/metabolismo , Laminina/química , Miofibroblastos/citología , Pericitos/citología , Proteoglicanos/química , Animales , Biopsia , Carcinoma/metabolismo , Diferenciación Celular , Línea Celular Tumoral , Colon/patología , Neoplasias Colorrectales/patología , Combinación de Medicamentos , Humanos , Ratones , Ratones Endogámicos BALB C , Trasplante de Neoplasias , Neovascularización Patológica
17.
J Histochem Cytochem ; 57(6): 543-57, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19223298

RESUMEN

Oral mucosal wounds heal with reduced scar formation compared with skin. The epithelial integrin alphavbeta6 is induced during wound healing, and it can activate fibrogenic transforming growth factor beta1 (TGF-beta1) and anti-fibrogenic TGF-beta3 that play key roles in scar formation. In this study, expression of beta6 integrin and members of the TGF-beta pathway were studied in experimental wounds of human gingiva and both gingiva and skin of red Duroc pigs using real-time PCR, gene microarrays, and immunostaining. Similar to human wounds, the expression of beta6 integrin was induced in the pig wounds 7 days after wounding and remained upregulated >49 days. The alphavbeta6 integrin was colocalized with both TGF-beta isoforms in the wound epithelium. Significantly higher expression levels of beta6 integrin and TGF-beta1 were observed in the pig gingival wounds compared with skin. Early gingival wounds also expressed higher levels of TGF-beta3 compared with skin. The spatio-temporal colocalization of alphavbeta6 integrin with TGF-beta1 and TGF-beta3 in the wound epithelium suggests that alphavbeta6 integrin may activate both isoforms during wound healing. Prolonged expression of alphavbeta6 integrin along with TGF-beta3 in the gingival wound epithelium may be important in protection of gingiva from scar formation.


Asunto(s)
Antígenos de Neoplasias/biosíntesis , Cicatriz/metabolismo , Integrinas/biosíntesis , Factor de Crecimiento Transformador beta/biosíntesis , Cicatrización de Heridas , Adulto , Animales , Femenino , Perfilación de la Expresión Génica , Encía/lesiones , Encía/metabolismo , Humanos , Inmunohistoquímica , Masculino , Mucosa Bucal/lesiones , Mucosa Bucal/metabolismo , Análisis de Secuencia por Matrices de Oligonucleótidos , Piel/lesiones , Piel/metabolismo , Porcinos , Factores de Tiempo , Factor de Crecimiento Transformador beta1/biosíntesis , Factor de Crecimiento Transformador beta3/biosíntesis , Adulto Joven
18.
Front Microbiol ; 10: 25, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30778337

RESUMEN

Infections caused by multidrug-resistant Pseudomonas aeruginosa in hospitalized patients are often fatal, and nosocomial infections caused by Guiana extended-spectrum (GES) ß-lactamase-producing strains are of growing concern. Several genotypes of the GES ß-lactamase gene (bla GES) include a single missense mutation, a change from G to A at nucleotide position 493 (G493A) that changes glycine to serine; the mutant enzyme exhibits carbapenemase activity. Rapid and reliable identification of drug-resistance is important in clinical settings; however, culture methods remain the gold standard. Conventional and real-time PCR cannot identify carbapenemase-producing genotypes, and direct DNA sequencing is essential. We established a novel loop-mediated isothermal amplification (LAMP) method to detect various genotypes of bla GES and another LAMP method to discriminate carbapenemase genotypes of bla GES. We evaluated the two assays using clinical P. aeruginosa strains. Two primer sets targeting bla GES (GES-LAMP) and the point mutation (Carba-GES-LAMP) were designed and evaluated for specificity and sensitivity. The detection limit of the GES-LAMP method was assessed using purified DNA and DNA-spiked clinical samples (urine, sputum, and blood). To determine the clinical usefulness of the methods, we used different (genotypically and phenotypically) P. aeruginosa clinical isolates, collected from diverse geographical locations between 2003 and 2012. The novel LAMP assay targeting bla GES was highly specific. The detection limit was 10 DNA copies per reaction; the assay was 10-fold more sensitive than conventional PCR. The LAMP assay detected bla GES with high sensitivity in all DNA-spiked samples; PCR did not detect bla GES in blood samples. The GES-LAMP method correctly detected the 5 isolates containing bla GES among the 14 isolates tested. Using these isolates, we confirmed that our Carba-GES-LAMP method of detecting point mutations correctly identified the two bla GES positive organisms with carbapenemase activity. To the best of our knowledge, this is the first report of the GES ß-lactamase gene detection assay using the LAMP method. Our new assays effectively detect bla GES and critical unique mutations.

19.
Brain Res ; 1188: 198-206, 2008 Jan 10.
Artículo en Inglés | MEDLINE | ID: mdl-18031717

RESUMEN

Reperfusion injury is a complication of recanalization therapies after focal cerebral ischemia. The disruption of the blood-brain barrier (BBB) caused by up-regulated metalloproteinases (MMPs) can lead to edema and hemorrhage. Middle cerebral artery occlusion (MCAO=90 min) and reperfusion (R=24 h vs. 5 days) was induced in male Wistar rats. Rats were randomized in four groups: (1) control (C), (2) twice daily minocycline (30 mg/kg bodyweight) every day (M), (3) hypothermia (33 degrees C) for 4 h starting 60 min after occlusion (H), (4) combination of groups 2 and 3 (MH). Serial MRI was performed regarding infarct evolution and BBB disruption, MMP-2 and MMP-9 were assessed by zymography of serum and ischemic brain tissue, and a functional neuroscore was done at 24 h and 5 days. M and H reduced both infarct sizes, volume and signal intensity of BBB breakdown and improved neuroscore at all points in time to the same extent. This was most likely due to inhibition of MMP-2 and MMP-9. The presence of MMP-9 at 24 h or MMP-2 at 5 days in brain tissue correlated with BBB breakdown whereas serum MMP-2- and -9 showed no relationship with BBB breakdown. The combination MH had a small but not significantly additional effect over the single treatments. Minocycline seems to be as neuroprotective as hypothermia in the acute and subacute phase after cerebral ischemia. One essential mechanism is the inhibition of MMPs. The combination therapy is only slightly superior. The net effect of MMPs inhibition up to 5 days after focal cerebral ischemia is still beneficial.


Asunto(s)
Barrera Hematoencefálica/efectos de los fármacos , Isquemia Encefálica/terapia , Hipotermia Inducida/métodos , Metaloproteasas/metabolismo , Minociclina/farmacología , Daño por Reperfusión/terapia , Enfermedad Aguda , Animales , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Barrera Hematoencefálica/metabolismo , Barrera Hematoencefálica/fisiopatología , Edema Encefálico/fisiopatología , Edema Encefálico/prevención & control , Edema Encefálico/terapia , Isquemia Encefálica/enzimología , Isquemia Encefálica/fisiopatología , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Infarto de la Arteria Cerebral Media/enzimología , Infarto de la Arteria Cerebral Media/fisiopatología , Infarto de la Arteria Cerebral Media/terapia , Hemorragias Intracraneales/fisiopatología , Hemorragias Intracraneales/prevención & control , Hemorragias Intracraneales/terapia , Imagen por Resonancia Magnética , Masculino , Metaloproteinasa 2 de la Matriz/metabolismo , Metaloproteinasa 9 de la Matriz/metabolismo , Minociclina/uso terapéutico , Fármacos Neuroprotectores/farmacología , Fármacos Neuroprotectores/uso terapéutico , Ratas , Ratas Wistar , Daño por Reperfusión/enzimología , Daño por Reperfusión/fisiopatología , Factores de Tiempo
20.
Matrix Biol ; 26(1): 20-9, 2007 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-17055234

RESUMEN

Fibrosis is the accumulation of extracellular matrix proteins and is a common end pathway in many chronic diseases. To identify novel mediators of fibrosis we used transcript profiling in a mouse model of kidney fibrosis, the COL4A3 knockout (alport) mouse. One gene that we found up-regulated in fibrotic kidney was GLIPR-2, also known as GAPR-1 and C9orf19, a member of the plant pathogenesis-related proteins family 1. We have found that GLIPR-2 protein expression is significantly increased in fibrotic kidney compared to healthy controls. Examination of the expression pattern of GLIPR-2 indicated that the protein is selectively expressed in epithelial cells. Co-staining with antibodies for alpha-smooth muscle actin expression, a marker of myofibroblasts, showed that GLIPR-2 expressing cells are closely apposed to areas of strong alpha-smooth muscle actin expression. The origin of these myofibroblasts is not known, but in vitro studies have shown that GLIPR-2 can induce epithelial to mesenchymal transition (EMT) in a renal epithelial cell line. We propose that increased GLIPR-2 expression in kidney contributes to development of fibrosis by increasing the pool of activated fibroblasts, possibly through the induction of EMT.


Asunto(s)
Diferenciación Celular/fisiología , Células del Tejido Conectivo/citología , Células Epiteliales/citología , Riñón/metabolismo , Proteínas/metabolismo , Actinas/metabolismo , Animales , Autoantígenos/genética , Cadherinas/metabolismo , Diferenciación Celular/efectos de los fármacos , Diferenciación Celular/genética , Línea Celular , Colágeno Tipo IV/genética , Células del Tejido Conectivo/efectos de los fármacos , Células del Tejido Conectivo/metabolismo , Modelos Animales de Enfermedad , Células Epiteliales/efectos de los fármacos , Células Epiteliales/metabolismo , Fibrosis , Perfilación de la Expresión Génica , Humanos , Inmunohistoquímica , Riñón/patología , Glomérulos Renales/metabolismo , Glomérulos Renales/patología , Médula Renal/metabolismo , Túbulos Renales/metabolismo , Túbulos Renales/patología , Proteínas de la Membrana/genética , Proteínas de la Membrana/metabolismo , Proteínas de la Membrana/farmacología , Ratones , Ratones Endogámicos , Ratones Noqueados , Proteínas/genética , Transfección , Vimentina/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA